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Factors in glucocorticoid regimens 
associated with treatment response 
and relapses of IgG4-related 
disease: a multicentre study
Mirei Shirakashi1, Hajime Yoshifuji1, Yuzo Kodama2, Tsutomu Chiba2,3, Motohisa Yamamoto4, 
Hiroki Takahashi4, Kazushige Uchida5, Kazuichi Okazaki5, Tetsuya Ito6, Shigeyuki Kawa7, 
Kazunori Yamada8, Mitsuhiro Kawano8, Shintaro Hirata9,10, Yoshiya Tanaka9, 
Masafumi Moriyama  11, Seiji Nakamura11, Terumi Kamisawa12, Shoko Matsui13, 
Hiroto Tsuboi14, Takayuki Sumida14, Motoko Shibata15, Hiroshi Goto15, Yasuharu Sato16, 
Tadashi Yoshino16 & Tsuneyo Mimori1
Glucocorticoids (GC) are effective for treating IgG4-related disease (IgG4-RD); however, relapse is often 
observed. We conducted a retrospective multicentre study to investigate risk factors in GC regimens 
associated with relapses of IgG4-RD. Data on 166 patients with definitive IgG4-RD diagnosis were 
collected from 12 institutions. Comprehensive surveillance of clinical backgrounds and GC regimens 
as well as multivariate analysis of factors associated with treatment responses and relapses was 
performed. To determine the initial maximal GC dose, the patients were stratified into three groups 
depending on the initial prednisolone (PSL) dosage: <0.39, 0.4–0.69 and >0.7 mg/kg/day. The 
multivariate analysis extracted the disease duration and reduction speed of initial GC dose. Patients 
treated with initial GC <0.39 or >0.7 mg/kg/day of PSL showed higher relapse rates than those treated 
with 0.4–0.69 mg/kg/day. The relapse rates were significantly higher in patients with fast reduction of 
the initial dose (>0.4 mg/day) than in patients with slow reduction (<0.4 mg/day). To avoid relapse, 
0.4–0.69 mg/kg/day of initial PSL with slow reduction speed (<0.4 mg/day) is needed in the early 
treatment of IgG4-RD.
IgG4-related disease (IgG4-RD) is a multiorgan sclerotic disease1,2 characterised by elevated serum IgG4 levels3,4 
and infiltration of IgG4-positive plasma cells into target organs2,5. However, its etiology and pathophysiology have 
not been sufficiently elucidated. Hamano et al.3 reported high serum IgG4 levels in patients with autoimmune 
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pancreatitis (AIP) in 2001, and several diseases such as Mikulicz disease4 have been also reported to be associated 
with IgG4. Consequently, a novel entity of IgG4-RD was established by integrating those diseases1. Patients with 
IgG4-RD respond to glucocorticoids (GC) effectively6–10, but relapse of the disease is observed frequently8,10–13. 
Because IgG4-RD mainly affects elderly people3,10,13,14, the long-term use of GC often harms these patients.
Although an initial dose of 0.6 mg/kg/day of prednisone or prednisolone (PSL) is often used to control 
IgG4-RD8,9, it is unclear if the initial dose and reduction speed of GC are suitable to control IgG4-RD. To refine 
the GC regimens, we performed a retrospective multicentre study on IgG4-RD. Because IgG4-RD is systemic, its 
study should not be biased by the specialties of the researchers. An outstanding point of this study is that a variety 
of specialists in gastroenterology, rheumatology, nephrology, dental and oral surgery, respiratory medicine, oph-
thalmology and pathology were involved.
Results
Patient profiles. Of the 166 patients (108 men, 65.1%; 58 women, 34.9%) who were evaluated, 140 fulfilled 
the comprehensive diagnostic criteria15 and 26 satisfied the Japan Pancreas Society’s diagnostic criteria for type 1 
AIP16. The age at onset was 61.2 ± 11.8 years old (range: 16–85). The disease duration was 6.2 ± 3.8 years, and the 
observation period was 5.4 ± 3.4 years for the first comprehensive surveillance. Figure 1a shows the number of 
patients with every affected organ. The total number of organs did not add up to the number of patients because 
most patients had multiorgan disease, and 34 (20.5%) had a single-organ disease (Fig. 1b). The average number 
of affected organs was 3.3 ± 2.2 (Fig. 1b). The maximal serum IgG4 concentration was 847.4 ± 621.1 mg/dL. Four 
patients whose maximal serum IgG4 levels were under 135 mg/dL were diagnosed using the diagnostic criteria 
for AIP.
Profiles of patients not treated with GC. Fourteen patients (8.4%) did not receive GC throughout the 
observation periods because they did not experience problems aside from cosmetic issues or because the lesions 
were removed surgically. Six patients had a single-organ disease. Two patients in whom an orbital tumour and 
pancreas were resected, respectively, were considered to be cured by surgery, and the disease did not recur.
Response to GC and later relapse. One hundred and fifty-two patients (91.6%) were treated with GC. The 
initial maximal GC dosage (PSL equivalent) per body weight was 0.55 ± 0.16 mg/kg/day in 150 patients whose 
data were available (Fig. 2). The response to GC could not be determined in 36 patients due to lack of clinical 
information. In the remaining 114 patients, 93 were responders (81.6%). According to the criteria of relapse, 
which are described in the Methods section, 46 (30.3%) of the 152 patients who were treated with GC experienced 
relapse. In the 46 relapsed patients, GC was increased in 42, steroid pulse therapy was performed in 2 and new 
Figure 1. (a) Number of affected organs. The total number does not add up because some patients had 
multiorgan diseases. Others included the liver (5), pituitary gland (4), skin (4), nerve (3), mammary gland (2), 
vocal cord (1), colon (1), palate (1), paranasal sinus (1), vertebral body (1), epicardium (1) and urethra (1). (b) 
Number of affected organs by the number of patients.
www.nature.com/scientificreports/
3SCIEnTIFIC REPORTS |  (2018) 8:10262  | DOI:10.1038/s41598-018-28405-x
immunosuppressants were added to GC in 2 patients. The peak GC dose after relapse was 21.6 ± 11.1 mg/day, 
excluding the 2 patients who received steroid pulse therapy.
Immunosuppressants. In the first surveillance in 2014, 9 (5.9%) of the GC-treated patients received immu-
nosuppressants. Six patients were treated with azathioprine (AZP) and the others received methotrexate, mizor-
ibine or cyclosporine A. One, three and five patients were treated only with immunosuppressants without GC at 
the first surveillance, at 12 months and 24 months, respectively, and all of them received AZP (Supplementary 
Fig. S1).
Factors associated with response and relapse. We compared the clinical backgrounds and GC regi-
mens between the patients with and without treatment responses and relapses, respectively (Table 1). We selected 
the following factors: sex, disease duration, maximal serum IgG4 concentration, number of affected organs, 
reduction speed of initial GC dose, reduction rates in the first 3 and 6 months and initial maximal GC dose. The 
relapsed group had a significantly longer disease duration (P = 0.02) and significantly higher reduction speed of 
initial GC dose (P < 0.01). We analysed the relationship between the initial maximum GC dosage and relapse 
rate (Supplementary Fig. S2). We classified the patients into 3 groups based on the initial PSL dosage: 1) high 
dosage in general: >0.7 mg/kg/day, 2) intermediate dosage, including the recommended 0.5–0.6 mg/kg/day15: 
0.4–0.69 mg/kg/day, and 3) low dosage: <0.39 mg/kg/day17. The rates of relapse among patients who were treated 
with GC <0.39, 0.4–0.69, and >0.7 mg/kg/day were 40.9%, 22.6%, and 54.2%, respectively (Table 1, right col-
umns). Thus, the relapse rates of patients treated with an initial PSL dosage of <0.39 or >0.7 mg/kg/day were 
higher than those of patients treated with 0.4–0.69 mg/kg/day.
Next, we analysed the association of these variables with relapses by univariate and multivariate analyses 
(Table 2). In the univariate analysis, disease duration, reduction speed of initial GC dose, and initial dose of GC 
>0.7 mg/kg/day (ref: 0.4–0.69 mg/kg/day) were extracted. In the multivariate analysis, disease duration, reduc-
tion speed of initial GC dose, and initial dose of GC <0.39 and >0.7 mg/kg/day (ref: 0.4–0.69 mg/kg/day) were 
extracted. Figure 3 shows the relapse rates in patient groups stratified by the reduction speed of the initial dose. 
Figure 2. Distribution of the initial maximal doses of glucocorticoid (GC) per body weight (converted to 
prednisolone doses).
Treatment response Relapse
Responder Non-responder Relapsed Non-relapsed
(n = 93) (n = 21) (n = 44) (n = 106)
Male: female 67:26 15:6 33:11 68:38
Disease duration (years) 5.60 ± 3.46 4.81 ± 3.31 7.43 ± 4.53 5.81 ± 3.45
Maximal serum IgG4 concentration (mg/dL) 837.40 ± 557.94 831.05 ± 550.83 826.80 ± 556.77 862.81 ± 631.78
Number of affected organs 3.35 ± 2.19 3.10 ± 2.07 3.43 ± 1.85 3.30 ± 2.18
Reduction rate in the first 3 months 0.60 ± 0.18 0.64 ± 0.23 0.64 ± 0.18 0.59 ± 0.17
Reduction rate in the first 6 months 0.75 ± 0.15 0.72 ± 0.19 0.77 ± 0.16 0.74 ± 0.14
Reduction speed of initial dose of GC (mg/day) 0.34 ± 0.38 0.34 ± 0.33 0.46 ± 0.57 0.29 ± 0.19
Initial dose of GC (%)
<0.39 mg/kg/day 64.50 35.50 40.91 59.09
0.4–0.69 mg/kg/day 85.90 14.10 22.64 77.36
>0.7 mg/kg/day 75.00 25.00 54.17 45.83
Table 1. Variables in patients with or without treatment responses and relapses. GC: glucocorticoid.
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The relapse rate in patients with fast reduction of the initial dose (>0.4 mg/day) was 47.6%, which is significantly 
higher than that (26.2%) in patients with slow reduction of the initial dose (<0.4 mg/day) (p = 0.04).
The rates of responders among patients who were treated with GC <0.39, 0.4–0.69 and >0.7 mg/kg/day were 
64.5%, 85.9% and 75.0%, respectively (Table 1, left columns). In the univariate and multivariate analyses, no vari-
ables associated with treatment response were extracted although low initial GC dose tended to be associated with 
non-responders (only the univariate analysis is shown in Table 3).
Supplementary Fig. S3 shows how GC was used at the time of relapse. GC was stopped by the time of relapse 
in 17 (37.0%) of the 46 patients who experienced relapse. In the 46 patients, the dose of PSL was 2.9 ± 3.2 mg/day, 
whereas in 29 (63.0%) patients, it was <5 mg/day.
Maintenance GC dose. In the first surveillance, 138 (90.8%) of the 152 GC-treated patients had a stable 
status and were either treated with maintenance dose or who had stopped GC (Supplementary Fig. S4). Thirty 
patients (21.7%) stopped GC, including 1 patient treated with AZP only. Forty-seven patients (34.1%) were 
treated with a maintenance GC dose <5 mg/day.
The average GC dose was 4.6–4.8 mg/day in the maintenance dose group at the 3 surveillance points 
(Supplementary Fig. S1). The 14 GC-untreated patients remained untreated at the 3 points.
Remission maintenance curve. The remission maintenance curve was plotted using the Kaplan-Meier 
method for the 152 GC-treated patients, with a maximal observation period of 185 months (Fig. 4). Relapse was 
observed in 8.0%, 14.8%, 27.1%, 37.5%, 52.4% and 57.1% of the patients at 12, 24, 48, 72, 96 and 120 months after 
the initial therapy, respectively.
Outcomes and adverse events. In the first surveillance, 2 (1.2%) of 163 patients were found to have died, 
and the causes of death were infection and cancer. Two patients transferred to another hospital, and their out-
comes were unknown. Two other patients had died at home of unknown causes at the time of the 24-month sur-
veillance (Supplementary Fig. S1). Side effects of GC were seen in 78 (51.3%) of the 152 GC-treated patients; these 
Variable
Univariate analysis Multivariate analysis
P value OR (95%CI) P value OR (95%CI)
Male (%) 0.19 1.68 (0.78–3.82) 0.07 2.41 (0.94–6.90)
Disease duration (years) 0.02 1.11 (1.02–1.22) 0.01 1.14 (1.03–1.28)
Maximal serum IgG4 concentration (mg/dL) 0.74 1.00 (0.99–1.00) 0.23 1.00 (0.99–1.00)
Number of affected organs 0.73 1.03 (0.87–1.22) 0.34 1.11 (0.89–1.39)
Reduction rate in the first 3 months 0.11 5.68 (0.70–48.86) NT
Reduction rate in the first 6 months 0.22 4.75 (0.40–65.29) NT
Reduction speed of initial dose of GC (mg/day) 0.01 4.53 (1.41–19.4) 0.02 6.19 (1.22–46.93)
Initial dose of GC (%)
   <0.39 mg/kg/day 0.09 2.37 (0.68–6.18) 0.02 3.83 (1.25–11.75)
   0.4–0.69 mg/kg/day ref ref ref ref
   >0.7 mg/kg/day <0.01 4.04 (1.61–10.35) 0.04 3.52 (1.09–11.51)
Table 2. Univariate and multivariate analyses of variables associated with relapses. Patients treated with initial 
GC <0.39 and >0.7 mg/kg/day of PSL were compared with patients treated with 0.4–0.69 mg/kg/day of initial 
PSL. Only reduction speed of initial dose of GC, but not reduction rate in the first 3 or 6 months, was included 
in the multivariate analysis. CI: confidence interval; GC: glucocorticoid; OR: odds ratio; NT: not tested; PSL: 
prednisolone; ref: reference.
Figure 3. Relapse rates stratified by reduction speed of the initial dose. *P < 0.05 (Fisher’s exact test).
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included diabetes (27.0%), dyslipidaemia (17.8%), osteoporosis (9.9%), hypertension (6.6%), infection (3.9%), 
cataracts (3.9%), osteonecrosis (2.6%), glaucoma (2.0%), insomnia (1.3%), psychosis (1.3%) and compression 
fracture (0.7%).
Discussion
We performed a retrospective, multicentre study on IgG4-RD to investigate risk factors in clinical backgrounds 
and GC regimens associated with relapses of IgG4-RD. A total of 84.3% of patients were definitively diagnosed 
with IgG4-RD based on the comprehensive diagnostic criteria of IgG4-RD15. Although IgG4-RD frequently 
occurs in the pancreas, biopsy of this organ has difficulties; therefore, we used the diagnostic criteria for AIP 
of the Japan Pancreas Society16, which included imaging findings and symptoms. We found that 79.5% of the 
patients had multiple lesions that affected various organs. Figure 1 shows that the selection of patients was well 
balanced among multiple specialty groups. The peak age at onset, sex ratio, high rate of GC responders, high 
relapse rate and remission maintenance curve in the present study were consistent with those of past reports6–13. 
The initial maximal GC dose per body weight (0.55 mg/kg/day) was slightly less than the 0.6 mg/kg/day that is 
recommended for treating AIP8,9.
We analysed the correlation between relapse and the initial maximal GC dose. Yamamoto et al.12 reported that 
a low GC dose at the initial treatment tended to be associated with relapse in IgG4-related dacryoadenitis and/or 
sialadenitis. In the present study, patients who were treated with <0.39 mg/kg/day of the initial PSL dose showed 
higher relapse rates than those treated with 0.4–0.69 mg/kg/day of initial PSL, suggesting that an initial dose of 
>0.4 mg/kg/day is appropriate. Paradoxically, the relapse rate of patients treated with >0.7 mg/kg/day of initial 
PSL was higher than that of patients treated with 0.4–0.69 mg/kg/day. This might be because a high dose of initial 
GC was selected in the treatment of atypically severe patients. The results imply that a high initial GC dose does 
not always lead to an improved relapse rate. Moreover, it leads to severer side effects of GC. Kamisawa et al.8,9  
recommended 0.6 mg/kg/day for the treatment of AIP, whereas Umehara et al.15 recommended 0.5–0.6 mg/kg/day 
for IgG4-RD according to the guidelines for AIP. Saeki et al.18 divided patients with IgG4-related kidney disease 
(IgG4-RKD) based on the PSL dosage (>0.6 and <0.6 mg/kg/day) and showed that there were no differences 
between the two groups in terms of renal function at 1 month after the initiation of GC therapy and relapse rate 
within the first 3 years. The authors suggested that 0.5 mg/kg/day might be sufficient for the initial therapy of 
IgG4-RKD. In the present study, the relapse rates were constantly low at intervals of 0.40–0.49, 0.50–0.59 and 
Variable P value OR (95% CI)
Male (%) 0.95 1.03 (0.38–2.84)
Disease duration (years) 0.58 1.08 (0.93–1.27)
Maximal serum IgG4 concentration (mg/dL) 0.96 1.00 (0.90–1.00)
Number of affected organs 0.61 1.06 (0.85–1.35)
Reduction rate in the first 3 months 0.47 0.38 (0.02–5.11)
Reduction rate in the first 6 months 0.53 2.64 (0.13–52.78)
Reduction speed of initial dose of GC (mg/day) 0.96 1.04 (0.32–6.45)
Initial dose of GC (%)
   <0.39 mg/kg/day 0.05 0.30 (0.09–1.01)
   0.4–0.69 mg/kg/day ref ref
   >0.7 mg/kg/day 0.36 0.49 (0.13–2.45)
Table 3. Univariate analysis of variables associated with treatment responses. Patients treated with initial GC 
<0.39 and >0.7 mg/kg/day of PSL were compared with patients treated with 0.4–0.69 mg/kg/day of initial PSL. 
CI: confidence interval; GC: glucocorticoid; OR: odds ratio; PSL: prednisolone; ref: reference.
Figure 4. Remission maintenance curve. This indicates the remission rates after the initial glucocorticoid (GC) 
therapy in the 152 GC-treated patients, with a maximal observation period of 185 months.
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0.60–0.69 mg/kg/day (23%, 25% and 18%, respectively), and the rates of responders seemed favourable in these 
intervals. Taken together, the recommended initial GC dose for IgG4-RD is 0.4–0.6 mg/kg/day.
We found a significant correlation between relapse and speed of GC reduction at the initial therapy. The 
patients with fast reduction of the initial dose (>0.4 mg/day) were at risk of relapse. The reduction speed of 
0.4 mg/day is equivalent to that of 5 mg PSL by 12.5 days after GC initiation. The duration of administration of the 
initial GC dose might suppress the activity of IgG4-RD and avoid relapse.
Regarding the maintenance dose, 90.8% of the GC-treated patients were treated with constant dose and about 
half of those patients took <5 mg/day in the first surveillance period. Similarly, in a Japanese database study by 
Yamamoto et al. (SMART)13, 92.1% of patients used a maintenance dose, and about half of them took <5 mg/day of 
GC. Kamisawa et al.8 reported that 82% of patients with AIP took a maintenance dose, and the majority took 5 mg/
day of PSL. In the present study, 37.0% of the relapsed patients had already stopped GC by the time of recurrence. 
In the relapsed patients, the GC dose at the time of relapse was 2.9 ± 3.2 mg/day, similar to the 3.2 ± 3.7 mg/day 
in the SMART registry13. Ghazale et al.19 reported that 53% of GC-discontinued patients experienced relapse of 
IgG4-associated cholangitis. Masamune et al.20 recently performed a multicentre randomised controlled trial 
using 49 patients with AIP and reported that patients who discontinued GC experienced relapse significantly 
more often (58%) than patients with maintained GC (23%, most took PSL 5–7.5 mg/day) in a 36-month observa-
tion period. Altogether, careful observation is needed when the GC dose is reduced below 5 mg/day.
In the present study, 7.9% of patients were treated with immunosuppressants, which is consistent with the 
rate of 9.0% in the SMART study13. In Japan, a maintenance GC dose tends to be used for relatively long periods, 
and immunosuppressants are used for a limited number of cases21 compared with the high rates (34.5–48%) of 
immunosuppressant use in European studies22,23.
The low mortality (1.2%) in the average observation period of 5.4 years and high frequency (51.3%) of side 
effects related to GC in the present study were consistent with rates of 3.6–4.0%22,23 and 67%22, respectively, in the 
European reports. The causes of death were not directly attributed to IgG4-RD in either the European studies or 
ours, although they were rather attributed to the side effects of GC.
This study has several limitation because of its retrospective nature. The responders and relapses were deter-
mined using information from the patients’ medical records. The proposed definition of responders and relapses of 
IgG4-RD that was used in this study should be validated in a prospectively designed study. Recently, Masaki et al.24  
conducted a prospective study of IgG4-RD (44 patients had a definite diagnosis), in which they used a unified 
GC dose. They started the trial with an initial dose of 0.6 mg/kg/day of PSL and reported a good response rate 
(93.2%). They reduced the dose of PSL by 10% biweekly and used a maintenance dose of 10 mg of PSL for at least 
3 months. The relapse rate in their study was low as 14.6%, suggesting that standardised prospective regimens will 
bring favourable outcomes.
In conclusion, careful and slow (<0.4 mg/day) tapering of GC is needed in the early treatment of IgG4-RD and 
when the GC dose is reduced below 5 mg/day.
Methods
Patients. One hundred and sixty-six patients who were definitively diagnosed with IgG4-RD through the 
comprehensive diagnostic criteria of IgG4-RD15 or the diagnostic criteria for type 1 AIP of the Japan Pancreas 
Society16 were collected from 12 institutions (13 departments) belonging to the Research Committee for the 
Study of Pathophysiology and Development of New Treatments in IgG4-RD of the Japan Agency for Medical 
Research and Development. All analyses were performed in accordance with approved guidelines and regula-
tions. Because this study is a non-invasive retrospective observational study, informed consent of patients was 
obtained in the opt-out way by disclosing information of the study on the internet. In advance, approvals of the 
study protocol including patient recruitment were acquired by ethical committees of all the institution. Clinical 
information was collected from the patients’ medical records. The cases were selected serially in each institution. 
The first comprehensive surveillance of outcomes, GC dose and use of immunosuppressants was performed in 
2014. These same factors were surveyed again 12 and 24 months later.
Definition of responders and relapse. A responder to therapy was defined as a patient who fulfilled one 
or more of the following items 4 weeks after initiation of the therapy: (1) improvement of organ function disorders 
such as decreased tear or salivary secretion, biliary obstruction and hydronephrosis; (2) the reduction of the tar-
get mass/organ’s diameter was >50% on physical examination, computed tomography (CT), magnetic resonance 
imaging (MRI) or 18F-fluorodeoxyglucose positron emission tomography CT (18F-FDG-PET-CT); or (3) the 
reduction of the target mass/organ’s diameter was >10% on physical examination, CT, MRI or 18F-FDG-PET-CT, 
and the reduction of serum IgG4 was >30%. If the patient has multiple organ involvements, he or she is regarded 
as a responder when the most prominent lesion fulfills the above criteria. Relapse of the disease was retrospec-
tively determined when (1) any emerging or worsening of existing organ function disorders, organ swelling or 
mass-forming lesions were detected on physical examination, CT, MRI, or 18F-FDG-PET-CT and (2) the GC 
dose was increased or (3) an immunosuppressant was newly added to the GC regimen to control the emerging or 
worsening symptoms of IgG4-RD.
To evaluate the reduction speed of GC, we surveyed (a) the initial GC dose (mg), (b) the GC dose (mg) 3 
months after initiation, (c) the GC dose (mg) 6 months after initiation, (d) the change at the first reduction 
from the initial GC dose (mg) and (e) the duration of the initial GC dose that was kept unchanged (days). Three 
parameters were defined as follows: (1) the rate of the reduction in the first 3 months: (a − b)/a, (2) the rate of 
the reduction in the first 6 months: (a − c)/a and (3) the speed of the reduction of the initial dose: d/e (mg/day).
The GC doses were converted to equivalent PSL doses.
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Statistical analysis. Student t-test was used for the comparison of unpaired groups. Variables were 
described as mean (±S.D.). In univariate and multivariate logistic regression analyses, results were expressed as 
odds ratios (OR) with the 95% confidence interval (CI). The remission maintenance curve was plotted using the 
Kaplan-Meier method. P < 0.05 was considered to be statistically significant. Statistical analyses were performed 
with JMP® software (SAS Institute Inc., Cary, NC, USA).
Data availability. All data generated or analysed during this study are included in this published article and 
its Supplementary Information files.
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